Clinical Study Of Xianlinggubao And Jintiange Capsules In Treating Type ? Osteoporosischinese Abstract

Objective: Clinical Study of Xianlinggubao and Jintiange Capsules in Treating Type ? Osteoporosischinese abstractMethods:1.According to the inclusion and exclusion criteria of this topic,120 postmenopausal osteoporosis patients were randomly divided into control group,treatment group A and treatment group B,with 40 cases in each group.2.Drug use plan: on the basis of basic treatment after alendronate sodium;alendronate sodium+ Jintiange;alendronate sodium+ Xianlinggubao3.Discuss the difference of treatment effect of the three groups of studies in postmenopausal osteoporosis patients and make economic evaluation on them.Results:1.after treatment,treatment group a is significantly lower than treatment group b in main syndrome(waist and back pain)and secondary syndrome(soreness of waist and knees)(p < 0.05),the total score of treatment group a and treatment group b is significantly lower than that of control group(p < 0.05),and the total score of treatment group a is significantly lower than that of treatment group b(p < 0.05).2.after treatment,EQ-5D symptom score(four movements,self-care,daily activities and discomfort)of treatment group a is significantly lower than that of control group(p < 0.05),EQ-5D symptom score(four movements,self-care and discomfort)of treatment group b is significantly lower than that of control group(p < 0.05),and the total score of treatment group a and treatment group b is significantly lower than that of control group(p < 0.05).3.the self-scores of treatment group a and treatment group b after treatment were significantly higher than those of control group(p < 0.05),and treatment group a was significantly higher than treatment group b(p < 0.05).4.there was no significant difference in bone mineral density among the control group,treatment group a and treatment group b before and after treatment(p > 0.05).5.the level of osteocalcin in the middle segment of the n-terminal and alkaline phosphatase after treatment in treatment group a and treatment group b is significantly lower than that in control group(p < 0.05).6.In terms of medication cost of the three groups,treatment group A is the highest,treatment group B is the second,and control group is the lowest.In terms of cost-effect ratio,treatment group B has the lowest cost-effect ratio,treatment group A takes second place,while control group has the highest cost-effect ratio.Conclusion:In this clinical study,the control group,treatment group A and treatment group B can all improve the osteoporosis symptoms of patients.Among them,the patients treated with alendronate sodium and Jintiange capsule have obviously relieved the symptoms and improved the quality of life.The patients treated by alendronate sodium+Xianlinggubao capsule can not achieve the effective rate of alendronate sodium+Jintiange capsule on the whole,but its medication cost-effect is the lowest,and the patients' economic pressure is relatively small in this medication scheme.Although the symptoms of patients taking alendronate sodium alone are relieved,they are not as good as those taking Jintiange capsule and Xianlinggubao capsule,and the cost-effectiveness of the drug is the highest.Therefore,drugs can be selected clinically according to the specific conditions of patients.